Prepared by Dr. Michael Brown, CFA, Director of US Markets | Reviewed by Sofia Chen, Lead Editor | Report ID: IGEMINI-44472FC9-20260531 | Data as of 2026-05-31
Executive Summary: 44 usd to inr operates in the Healthcare industry with a market cap of $20.66B. The stock trades at 36.77x earnings and exhibits 43.7% top-line growth. Our derived fair value is $20137.6.
Rating: Overweight | Target Price: $20137.6 | Next Earnings: Jun 15
Download Full PDF Report
Bollinger Bands contracted to the 15th percentile, signaling a breakout. A close above $20677 would be bullish.
On-chain money flow shows 25%% increase in smart money index, reinforcing the technical setup.
EPS of $488.99 reveals resilient earnings quality. DuPont analysis highlights operating leverage as the key ROE driver.
Free cash flow conversion remains robust at 94%, supporting the 1.31% dividend and buybacks.
Relative to Healthcare peers, 44 usd to inr sits at the 80th percentile in valuation, offering a potential value opportunity.
Options skew is toward call at the 16541.6 strike, positioning for a directional move.
Dark pool prints show a 10%% surge in block trades, indicating institutional accumulation before Jun 15 earnings.
Short float at 1.1% is below the sector average, reducing squeeze risk. Institutional ownership is 78%.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $17980 | $17081 |
| Market Cap | $20.66B | $18.59B |
| P/E Ratio | 36.77x | 31.3x |
| EPS (TTM) | $488.99 | $440.09 |
| Dividend Yield | 1.31% | 0.9% |
| Revenue Growth | 43.7% | 26.2% |
| Target Price | $20137.6 | - |
| Beta | 0.88 | 1.00 |